LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

Search

BioNTech SE ADR

Cerrado

Sector Salud

124.48 0.76

Resumen

Variación precio

24h

Actual

Mínimo

121.76

Máximo

131.02

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

-4.72 downside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2024

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

124 / 366 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

BioNTech SE ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 may 2024, 11:27 UTC

Ganancias

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

20 mar 2024, 10:44 UTC

Ganancias

BioNTech Profit Slumps on Lower Covid Vaccine Sales

8 feb 2024, 11:43 UTC

Adquisiciones, fusiones, absorciones

BioNTech Agrees To Invest $200 Million in Autolus, Starts Strategic Collaboration

5 ago 2024, 10:02 UTC

Ganancias

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 ago 2024, 10:01 UTC

Ganancias

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 ago 2024, 10:01 UTC

Ganancias

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 ago 2024, 10:00 UTC

Ganancias

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Loss EUR807.8M >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 ago 2024, 09:59 UTC

Ganancias

BioNTech 2Q Rev EUR128.7M >BNTX

6 may 2024, 20:15 UTC

Ganancias

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

6 may 2024, 10:47 UTC

Ganancias

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

6 may 2024, 10:46 UTC

Ganancias

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

6 may 2024, 10:46 UTC

Ganancias

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

6 may 2024, 10:46 UTC

Ganancias

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

6 may 2024, 10:45 UTC

Ganancias

BioNTech 1Q Rev $187.6M >BNTX

6 may 2024, 10:45 UTC

Ganancias

BioNTech 1Q Loss $315.1M >BNTX

6 may 2024, 10:45 UTC

Ganancias

BioNTech 1Q Loss/Shr $1.31 >BNTX

26 mar 2024, 05:00 UTC

Ganancias

This Vaccine Maker Sits on Cash Almost Equal to Its Market Value -- Barrons.com

20 mar 2024, 11:44 UTC

Ganancias

BioNTech Earnings Fall Short of Estimates. The Stock Is Down. -- Barrons.com

20 mar 2024, 10:27 UTC

Ganancias

BioNTech's Stock Sinks After Earnings Fall Below Expectations, Hurt By Writedowns Of Vaccine Inventory -- MarketWatch

20 mar 2024, 10:17 UTC

Ganancias

BioNTech 4Q Rev EUR1.48B >BNTX

20 mar 2024, 10:15 UTC

Ganancias

Biontech 4Q Net Pft EUR457.9M

20 mar 2024, 10:15 UTC

Ganancias

Biontech Plans For Ten or More Registrational Oncology Trials By End of 2024

20 mar 2024, 10:15 UTC

Ganancias

Biontech: Annemarie Hanekamp appointed to Management Board as Chief Commercial Officer, effective Jul. 1

20 mar 2024, 10:15 UTC

Ganancias

Biontech Aims For First Oncology Launch in 2026 and Ten Indication Approvals by 2030

20 mar 2024, 10:15 UTC

Ganancias

Biontech 2023 Gross Profit For COVID-19 Vaccine Business EUR3.2B

20 mar 2024, 10:15 UTC

Ganancias

Biontech Sees 2024 Revenue Between EUR2.5B - EUR3.1B

20 mar 2024, 10:15 UTC

Ganancias

Biontech 4Q Rev EUR1.48B

8 feb 2024, 11:28 UTC

Adquisiciones, fusiones, absorciones

BioNTech Agrees To Invest $200 Mln in Autolus, Starts Strategic Collaboration

Comparación entre iguales

Cambio de precio

BioNTech SE ADR Esperado

Precio Objetivo

By TipRanks

-4.72% caída

Estimación a 12 meses

Media 117.64 USD  -4.72%

Máximo 171 USD

Mínimo 85 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioNTech SE ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

7

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

105.07 / 129.38Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

124 / 366 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media